Organizations
- Johnson & Johnson
FDA approved Imaavy for adults and adolescents age 12 and older with warm autoimmune hemolytic anemia who are receiving or have previously received corticosteroids. Johnson & Johnson says the pivotal study produced roughly three times as many durable hemoglobin responders at the approved dose as placebo; Fierce Pharma separately covered the label expansion.
What happened
- FDA expanded Imaavy's label to warm autoimmune hemolytic anemia in patients age 12 and older who are receiving or have previously received corticosteroids.
- Johnson & Johnson reported that the approved dose produced roughly three times as many durable hemoglobin responders as placebo in a randomized study of 115 adults.
Why it matters
Warm autoimmune hemolytic anemia can destroy red blood cells faster than the body replaces them. A disease-specific approval gives clinicians an alternative to relying only on corticosteroids and other off-label immunosuppressive treatment.
Key details
- Population
- Adults and adolescents age 12 and older receiving or previously treated with corticosteroids
- Pivotal study
- 115 adults randomized 1:1:1 across two Imaavy doses and placebo
- Approved dose result
- About three times as many durable hemoglobin responders as placebo, according to J&J
What to watch
- How quickly physicians adopt FcRn blockade and whether longer follow-up changes the treatment's risk-benefit profile.
Event chronology
How the story developed
FDA approval announced
Johnson & Johnson announced the U.S. label expansion for warm autoimmune hemolytic anemia.
Evidence ledger
Sources behind this brief
- 01Primary source
Johnson & Johnson approval announcement
company announcement · Accessed August 25, 2026
- 02